NCT06515821Recruiting
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
Multicentre Observational Study for the Data Collection, Development and Evaluation of the Performance of Novel CRC Screening and Diagnostic Methods ONCOSCREEN-CS
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 4100 (estimated)
- First submitted
- 28 Jun 2024
- Start date
- 1 Aug 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Firalis SA
- Diseases
- Colorectal cancer
- NCT number
- NCT06515821
What you commit to
- Study type: Observational
- Planned participants: 4100
- From 1 Aug 2024 to the primary completion date, 31 Dec 2026
- 8 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For the CRC Group
- Legal incapacity or limited legal capacity
- Subject did not sign the Informed Consent form
- Subject who, according to the investigator's assessment, presents with an unstable medical condition contraindicating the performance of the planned blood test, stool test or breath test
- Subject has had surgery in the previous 6-8 weeks or is under medication for CRC treatment.
- For the control groups
- Legal incapacity or limited legal capacity
- Subject did not sign the Informed Consent form
- Previous history of any type of cancer
- Gastrointestinal disorders or other serious acute or chronic diseases
Who the study is looking for
- CRC Group
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Subject is willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject for whom the decision to perform a colonoscopy has been made by the treating physician
- Subject has positive CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System
- Subject is able to comply with all study procedures
- Control Group with risks and presence of polyps
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
- Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject has negative CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with risks and absence of polyps
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
- Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject has negative CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with no risks
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥40 years
- Otherwise healthy individuals without any recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidemia.
- Subject be willing to undergo FOBT test
- Subject has negative FOBT result
Age in the registry: 18 years to - · Sex: All
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Military Medical Academy Sofia, Gastroenterology Clinic, 3 Sveti Georgi Sofiiski str., Sofia 1606, Bulgaria Coordinator of this site? Confirm its status | Sofia | Bulgaria | Recruiting |
| University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology. Coordinator of this site? Confirm its status | Sofia | Bulgaria | Not yet recruiting |
| MKI UKSH Lübeck Coordinator of this site? Confirm its status | Lübeck | Germany | Recruiting |
| UMC Mainz: University Medical Center Mainz Coordinator of this site? Confirm its status | Mainz-GE | Germany | Recruiting |
| UFC: Université de Franche-Comté Oncology department CHU Besançon Coordinator of this site? Confirm its status | Besançon | France | Not yet recruiting |
| LSMU: Lithuanian University of Health Sciences Gastroenterology Department, Coordinator of this site? Confirm its status | Kaunas | Lithuania | Recruiting |
| IPO: Instituto Português de Oncologia Coordinator of this site? Confirm its status | Porto | Portugal | Recruiting |
| IBO: Institutul Oncologic Prof. Dr. Alexandru Trestioreanu București Coordinator of this site? Confirm its status | Bucharest | Romania | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.